Jubilant Generics receives FDA approval for Tadalafil ANDA210329
Jubilant Generics has received an Abbreviated New Drug Application (ANDA) approval for Tadalafil.
Published: July 18, 2026
Updated: July 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Urology / PDE5 Inhibitor
Asset: Tadalafil
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Tadalafil
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA approval of Jubilant Generics for Tadalafil introduces a new competitor in the PDE5 inhibitor market, which could disrupt existing market dynamics. Portfolio teams must evaluate the potential impact on pricing and market share for current Tadalafil products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies from Jubilant Generics and competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.